EP Patent

EP2205236A4 — Novel agents for treatment of ailments and dysfunctions

Assigned to Regain Biotechnology Pvt Ltd · Expires 2012-08-22 · 14y expired

What this patent protects

Patent listed against Estrace.

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

Patent Metadata

Patent number: EP2205236A4
Jurisdiction: EP
Classification: —
Expires: 2012-08-22
Drug substance claim: No
Drug product claim: No
Assignee: Regain Biotechnology Pvt Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.